Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CCR4 | P51679 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038743 | 0.89 | HTT (0.51) | SCN9ACCR4ARHTTSMN1; SMN2 | |
| SCHEMBL6038438 | 0.89 | CCR4 (0.54) | SCN9ACCR4ARCYP2C19HTT | |
| SCHEMBL6039001 | 0.89 | MEN1 (0.53) | SCN9ACCR4ARMEN1KMT2A | |
| SCHEMBL6038997 | 0.88 | NAMPT (0.51) | SCN9ACCR4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6039079 | 0.87 | HTT (0.55) | ARCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6038733 | 0.86 | SCN9A (0.50) | SCN9ACCR4HTTSMN1; SMN2MEN1 | |
| SCHEMBL6039075 | 0.85 | KDM4E (0.53) | SCN9ACCR4ARHTTSMN1; SMN2 | |
| SCHEMBL6039159 | 0.80 | CCR4 (0.58) | SCN9ACCR4HTTSMN1; SMN2MEN1 | |
| SCHEMBL6038356 | 0.79 | MEN1 (0.46) | CCR4ARCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6038939 | 0.79 | AR (0.49) | CCR4ARCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | SCN9A 2242/4885CCR4 1/4885AR 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.